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apeutic efﬁcacy. Furthermore, analysis of patients from the POSEIDON-
DCM and TRIDENT trials showed that intracardiac administration of
allogeneic, but not autologous MSCs improved endothelial function 3
months after treatment (Premer et al., 2015).
The patient population and their different types of HF complicate the
ongoing search for the best stem cell to improve cardiac function. MostThe advent of stem cell and cell-based therapy has opened the door type. Therefore it is not ideal to target one cell line and call it “theto a non-pharmacological treatment of heart failure (HF). This exciting
opportunity is at an early stage andmany issues regarding optimization
of this approach remain. A variety of stem cells (SCs), doses, and deliv-
erymethods are being tested in clinical trials, supporting the conclusion
that there is still “no consensus on… which cell type to transplant, to
improve efﬁcacy and safety” (Silvestre andMenasché, 2015). To provide
a guide going forward, Silvestre andMenasché take us through the evo-
lution of the therapeutic use of SCs for heart failure (Silvestre and
Menasché, 2015). Their main proposal is that “cardiac-committed
cells” in general and “pluripotent stem cell-derived cardiac progenitors”
in particular are “particularly attractive” candidates for cell therapy.
Many clinical trials have suggested SC efﬁcacy. While early trials
have focused on attempting to show improvements in morphologic
measures such as left ventricular ejection fraction (LVEF), end diastolic
volume (LVEDV), end systolic volume (LVESV), ventricular mass and
scar size, others have attempted to examine surrogate clinical endpoints
such as 6-min walk distance and Minnesota Living with Heart Failure
scores. To adequately address which cell type is superior, direct cell-
to-cell comparisons in pre-clinical studies on large animals and in clin-
ical trials are needed. To date, numerous clinical and pre-clinical studies
illustrate the therapeutic beneﬁts of mesenchymal stem cells (MSCs),
regardless of their tissue source. For example, in the TAC-HFT trial,
MSCs improved cardiac function in chronic ischemic cardiomyopathy
equal to or better than BM-mononuclear cells (Heldman et al., 2014).
The POSEIDON clinical trial compared intra-myocardial injection of
autologous and allogeneic bone marrow-derived (BM-) MSCs, and
demonstrated a signiﬁcant reduction in LVEDV in the allogeneic group
(Hare et al., 2009). Unexpectedly, there appears to be an inverse
relationship between cell number (20million vs. 200million) and ther-m.2015.11.010.
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pen access article under the CC BY-Nstudies have focused on ischemic cardiomyopathy; however, acute and
chronic diseases do not necessarily respond similarly to a given cell
best”. Instead it may be more advantageous for us to ask the question:
are the parameters we focus on, such as EF, the best predictor of future
morbidity andmortality?Many factors play a role in global EF; therefore
segmental changes in EF may provide a better correlation with clinical
outcomes. Clinical trials that have failed to produce the best results
with respect to EF nevertheless improved quality of life as indicated
by improvements in the Minnesota Living with Heart Failure score
and the 6-min walk test (Sanina and Hare, 2015).
Silvestre and Menasché propose that cardiac-committed cells are
superior therapeutically. However, in direct comparisons between
MSCs and either induced pluripotent cell-derived cardiomyocytes
(Weil et al., 2015) (iPSC-CM) or cardiosphere-derived cells (CDCs)
(Li et al., 2012), MSCs provided equal cardiac functional improvements
compared with both of these “cardiogenic” cell types except that MSCs
were less effective at scar size reduction. Future therapies may be best
served by combining cells. Recent studies show that the combination
of c-kit + cardiac stem cells (CSCs) with either MSCs (Karantalis et al.,
2015; Williams et al., 2013) or CDCs (Li et al., 2012) is more effective
at restoring cardiac function than CSCs (Williams et al., 2013) or MSCs
(Karantalis et al., 2015; Williams et al., 2013) alone in pig models of
HF. In a recent murine study, Quijada et al. showed that a fusion of
CSCs with MSCs was superior to the individual cells in improving left
ventricular function and structure (Quijada et al., 2015). Perhaps cardio-
genic cells are superior, and this property is manifested when they are
combined with another cell type. Another approach is to pre-incubate
or co-inject cytokines (or other factors) with cells.
Regardless of the cell type or injection route, SCs exhibit limited
engraftment in the heart, suggesting that much of their effect is due
to their paracrine release of growth factors, mitochondria, and/or
exosomes. Silvestre and Menasché suggest that allogeneic cells are
superior “biofactories” compared with autologous cells and produce
higher levels of (or better) paracrine factors. Therefore, the milieu
from which the cell is isolated may promote favorable interactions
and prime cells to increase their production of growth factor(s), a prop-
erty that may be more important than the type of cell used. The use ofC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1839B. Tompkins et al. / EBioMedicine 2 (2015) 1838–1839stem cells therapeutically is still at an investigational stage andmany of
these questions will remain unanswered until rigorous head to head
clinical trials are performed with clinical outcomes.
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